Although there are ongoing clinical trials investigating the efficacy of PI3K inhibitors in breast cancer, no specific trials are currently focused solely on targeting PIK3R1 in TNBC Our findings, supported by both STRING network insights and differential expression profiles, highlight the potential of targeting the PI3K/AKT/mTOR pathways in breast cancer subtypes. This evidence concerns the gene PIK3CD and breast cancer.